Contact us

Please complete the form below and a member of the BOTOX^® (botulinum toxin type A) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

BOTOX^® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.¹

The BOTOX^® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page.

First name:*

Please enter First name

Last name:*

Please enter Last name

E-mail address:*

E-mail address is not valid

Hospital name:*

Please enter Hospital name

Hospital postcode:*

Please enter Hospital postcode

Please select the items you are interested in:

BOTOX® dosing and administration guide

Urology nurse resource checklist

Urology service development guide

BOTOX® budget impact model

Patient Guide for BOTOX® (botulinum toxin type A): overactive bladder

Patient Guide for BOTOX® (botulinum toxin type A): neurogenic detrusor overactivity

Please select one field.

Request a meeting with your local AbbVie Key Account Manager

I consent to receive AbbVie Ltd communications about its products, services, research, events, programmes and other information, including promotional content, that may be of interest to me, using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.

References

1. BOTOX^® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed April 2024

References

1. BOTOX^® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc /product/859/smpc. Accessed April 2024

Please refer to the BOTOX^® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

BOTOX® PRESCRIBING INFORMATION

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

Date of preparation: April 2024. UK-BUO-240011.

Contact us

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome